Close

Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share

August 7, 2014 6:51 AM EDT

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), which may not compare with the analyst estimate of ($0.76). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $4.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings